ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
November 26 2012 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops anticancer therapeutics using its Targeted Antibody
Payload (TAP) technology and antibody expertise, today announced
the appointment of Charles Morris, MB, ChB, MRCP as Executive Vice
President and Chief Development Officer, effective today. Dr.
Morris will be responsible for leading all aspects of product
development, including regulatory, at ImmunoGen. He reports to
Daniel Junius, President and Chief Executive Officer.
“Charlie has extensive experience leading the strategic
development and registration of novel oncology compounds –
expertise essential to ImmunoGen with our advancing and expanding
product pipeline,” commented Mr. Junius. “We now have three wholly
owned clinical-stage compounds, expect to advance our fourth
product candidate into the clinic in 2013, and have additional
highly promising compounds behind these in our pipeline. We are
excited to have Charlie joining ImmunoGen at this important time in
our transition to being a product development company.”
Dr. Morris brings to ImmunoGen nearly twenty years of experience
in the development of anticancer compounds, including experience
with registration clinical trials, regulatory approvals,
pharmacovigilance, and medical affairs support for marketed
products. Prior to joining ImmunoGen, he was the executive vice
president and chief medical officer at Allos Therapeutics, Inc.,
where he led the company’s clinical development functions including
clinical operations, regulatory, and pharmacovigilance. Prior to
joining Allos in 2010, Dr. Morris was vice president worldwide
clinical research at Cephalon, Inc., where he contributed
significantly to the company achieving its first approved oncology
drug, Treanda® (bendamustine). Prior to joining Cephalon in 2007,
Dr. Morris was with AstraZeneca Pharmaceuticals (formerly Zeneca
Pharmaceuticals), serving most recently as vice president, clinical
development projects, oncology. Dr. Morris held a number of
leadership roles during his more than ten years with AstraZeneca,
including managing the clinical development of all late-stage
pipeline and marketed oncology products.
Dr. Morris holds Degrees of Bachelor of Medicine, Bachelor of
Surgery, and Bachelor of Medical Science in Clinical Pharmacology
and Therapeutics from the Sheffield University Medical School, UK,
and is a member of the Royal College of Physicians of London.
About ImmunoGen’s Wholly Owned Product Candidates
The Company currently has three wholly owned anticancer
compounds in clinical testing – IMGN901, in Phase II testing for
the treatment of small-cell lung cancer; IMGN853, in Phase I
testing for the treatment of ovarian, lung, and other cancers that
over-express folate receptor 1; and IMGN529, in Phase I testing for
the treatment of non-Hodgkin’s lymphoma. ImmunoGen intends to use
the findings from these clinical trials to define the registration
paths for these compounds. The Company also expects to advance a
fourth compound into the clinic in 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its Targeted Antibody Payload (TAP) technology together with the
Company’s expertise in monoclonal antibodies and tumor biology. A
TAP compound uses a tumor-targeting monoclonal antibody to deliver
one of ImmunoGen's purpose-developed cancer-killing agents
specifically to tumor cells. Ten TAP compounds are now in clinical
testing, of which three are wholly owned by the Company. Marketing
applications for trastuzumab emtansine (T-DM1), the most advanced
compound using ImmunoGen's TAP technology, are under review in the
US and Europe. Roche is developing this compound globally under an
agreement between ImmunoGen and Genentech, a member of the Roche
Group. More information about ImmunoGen can be found at
www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen’s Annual Report on Form 10-K for
the fiscal year ended June 30, 2012 and other reports filed with
the Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2023 to Aug 2024